| Today’s Big NewsSep 20, 2023 |
| By Andrea Park Neuralink is looking for volunteers who have quadriplegia caused by a spinal cord injury or ALS, according to a company blog post. |
|
|
|
| Virtual Event |  |
|
|
By James Waldron PeptiDream is clearly doing something right. Big Pharmas have been queueing round the block to collaborate on the Japanese biotech’s peptide discovery platform, and, now, long-term partner Genentech is back with $40 million in upfront cash for a fresh licensing agreement. |
By Zoey Becker UCB had previously expected an FDA decision during the first half of the year after suffering a prior rejection on its medicine. But now the company warned a decision will likely be delayed past the third quarter. |
By Kevin Dunleavy Two CDMOs have revealed acquisitions that will bolster their production capabilities and increase their global footprint. Korea's SK pharmteco has taken a controlling stake in the Pennsylvania-based Center for Breakthrough Medicines for an undisclosed sum. Meanwhile, England’s Oxford Biomedica said it is in talks with Institut Merieux to buy out its subsidiary, ABL Europe, for 15 million euros ($16 million). |
|
October 16-18, 2023 | Boston, MA Brought to you by the editors behind Fierce Biotech, this conference is a unique venue where biotech executives can network and learn how to improve their partnership and pipeline strategies. It’s the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials. Countdown is on! Register today to save $200 
|
|
By Nick Paul Taylor Merck KGaA is spreading its bets on an artificial-intelligence-enabled future for drug discovery, inking similar three-target deals with BenevolentAI and Exscientia. The deals are collectively worth more than $30 million upfront and $1 billion in potential milestones. |
By Conor Hale According to the company, its Versius system counts more than 140 installations in international hospitals, which to date have been used to conduct more than 15,000 keyhole surgeries. |
By Angus Liu The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. And the company won’t get distracted from its long-term strategy, he said. |
By Nick Paul Taylor Astellas has turned down the chance to option an asset from Taysha Gene Therapies. And with Taysha identifying study design feasibility challenges after talking with the FDA, the biotech has stopped internal development of the candidate and added it to a large pile of dropped and deprioritized programs. |
By Andrea Park Joining Novo Nordisk's GLP-1 assembly line is Ypsomed, which has signed on to produce “large quantities of autoinjectors” for the Danish drugmaker. |
By Fraiser Kansteiner Positive FDA advisory committee votes aren’t always a blueprint for approval. ARS Pharmaceuticals learned that lesson the hard way, as the FDA issued a surprise rejection of its anaphylaxis nasal spray Neffy. |
By Max Bayer Nadir Mahmood is taking his first CEO gig leading Rezo Therapeutics, which spun out of UCSF and is chaired by longtime biotech exec George Scangos. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Tuesday, September 26, 2023 | 11am ET / 8am PT This webinar will focus on the latest advancements in bioprocessing for cell and gene therapies (CGTs), including the improved consistency and reduced production costs associated with closed manufacturing. Register now. 
|
|
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
